Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Homburg – page 53

1 595 clinical trials in Bad Homburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Homburg at a glance
1 595
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 595 trials in Bad Homburg

Open in trial search

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of combination therapy with an endothelin receptor antagonist, phosphodiesterase‑5 inhibitor, and sotatercept in newly diagnosed pulmonary arterial hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Philipps-Universitaet Marburg

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Diabetic retinal oedema

Not yet recruiting

Efficacy and safety of intravitreal MK-8748 versus aflibercept in adults with diabetic macular edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Astrocytoma

Not yet recruiting

Safety and Immunogenicity Study of IDH1 Peptide Vaccine and Vorasidenib in Adults with Recurrent IDH1R132H‑Mutant Astrocytoma (Grades 2‑4)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:Heidelberg University

Major depression

Not yet recruiting

Efficacy and Safety of AGN-151607-DP in Adults with Major Depressive Disorder: A Randomized, Placebo‑Controlled Phase 2 Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Homburg

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focusing on Alzheimer's Disease treatments and innovative therapies for Multiple Sclerosis. Studies are evaluating new compounds for disease modification and symptom management.

  • Early-stage Alzheimer's interventions
  • Relapsing-remitting MS treatments
  • Parkinson's Disease management

Additional trials explore treatments for migraine in both adults and pediatric populations.

02 Cardiovascular Research

Comprehensive studies targeting cardiovascular diseases and related conditions, including innovative approaches to treating atherosclerosis and managing blood pressure.

  • Cholesterol management therapies
  • Hypertension treatments
  • Atherosclerotic disease interventions

Focus on preventive treatments and long-term cardiovascular health maintenance.

03 Oncology Studies

Advanced clinical research in gynecologic oncology, including trials for ovarian and endometrial cancers, plus innovative approaches for colon cancer treatment.

  • Ovarian cancer therapeutics
  • Endometrial cancer treatments
  • Targeted cancer therapies

Emphasis on combination therapies and personalized treatment approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.